×
0.00652173913043488 0.00652173913043488 0.00652173913043488 0.00652173913043488 0.011304347826087 0.0147826086956522 0.0141304347826087 0.0147826086956522
Stockreport

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

argenx SE ADS (ARGX)  More Company Research Source: GlobeNewswire
PDF Subcutaneous formulation intended for chronic therapy setting October 30, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that the first subject has been dosed in a Phase I clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of a subcutaneously administered formulation of ARGX-113 in healthy volunteers.   "We are developing a subcutaneous formulation of ARGX-113 to offer greater convenience for patients with severe auto-immune conditions requiring long term treatment.  This treatment option could represent a significant advancement over current standard of care in the treatment of these types of chronic diseases," commented Nicolas Leupin, Chief Medical Officer of argenx. "In preclinical studies, we were high [Read more]

IMPACT SNAPSHOT EVENT TIME: ARGX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
ARGX alerts

from News Quantified
Opt-in for
ARGX alerts

from News Quantified